Small-cap stocks in the Russell 2000 can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco (NYSE:ELAN).
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting with Amphastar Pharmaceuticals (NASDAQ:AMPH).
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP)
jumped 13.4% in the pre-market session after the company reported strong fourth-quarter 2024 results, significantly surpassing analysts' revenue expectations. Revenue surged 45% year-on-year, fueled by continued growth in its Rare Disease segment. Purified Cortrophin Gel led the way with a 42% rise, while the newly added ILUVIEN and YUTIQ products also boosted sales.
The company raised its 2025 outlook, now expecting sales to climb up to 26% and earnings per share to grow as much as 25%.
Overall, the quarter showed strong sales growth and smart investments.
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year revenue guidance of $766 million at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 13.6% above analysts’ consensus estimates.
ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQ:VTRS).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Amneal (NASDAQ:AMRX).
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial sales growth and an optimistic FY 2024 outlook.
